Ameriprise
CTKB icon

Ameriprise’s Cytek Biosciences CTKB Stock Holding History

Ameriprise’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.6K Sell
14,126
-173,144
-92% -$739K ﹤0.01% 4050
2026
Q1 		$818K Sell
187,270
-15,046
-7% -$71K ﹤0.01% 3393
2025
Q4 		$1.02M Sell
202,316
-126,307
-38% -$586K ﹤0.01% 3317
2025
Q3 		$1.14M Sell
328,623
-83,688
-20% -$314K ﹤0.01% 3298
2025
Q2 		$1.4M Buy
412,311
+134,963
+49% +$450K ﹤0.01% 3123
2025
Q1 		$1.11M Buy
277,348
+27,980
+11% +$145K ﹤0.01% 3170
2024
Q4 		$1.62M Sell
249,368
-104,073
-29% -$620K ﹤0.01% 3035
2024
Q3 		$1.96M Buy
353,441
+85,805
+32% +$487K ﹤0.01% 2928
2024
Q2 		$1.49M Sell
267,636
-21,920
-8% -$132K ﹤0.01% 2995
2024
Q1 		$1.94M Sell
289,556
-10,196
-3% -$80.6K ﹤0.01% 2885
2023
Q4 		$2.73M Sell
299,752
-17,571
-6% -$111K ﹤0.01% 2713
2023
Q3 		$1.75M Sell
317,323
-286,838
-47% -$2.3M ﹤0.01% 2881
2023
Q2 		$5.16M Buy
604,161
+347,911
+136% +$3.12M ﹤0.01% 2324
2023
Q1 		$2.35M Buy
256,250
+373
+0.1% +$4.01K ﹤0.01% 2766
2022
Q4 		$2.61M Sell
255,877
-28,074
-10% -$377K ﹤0.01% 2694
2022
Q3 		$4.18M Buy
283,951
+7,749
+3% +$101K ﹤0.01% 2349
2022
Q2 		$2.96M Buy
+276,202
New +$2.75M ﹤0.01% 2621
2021
Q4 		– Sell
-87,634
Closed -$1.88M – 3976
2021
Q3 		$1.88M Buy
+87,634
New +$2.06M ﹤0.01% 2896

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameriprise's CTKB Position: Q2 2026 in Review

Ameriprise reduced its Cytek Biosciences (CTKB) stake by 92% in Q2 2026, selling an estimated $739K and leaving 14,126 shares worth $62.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4050.

Ameriprise first reported a position in CTKB in Q3 2021 and has held it in 18 quarters since. The position peaked at $5.16M in Q2 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Ameriprise held 14,126 shares of Cytek Biosciences worth $62.6K as of Q2 2026.
  • Ameriprise sold 173,144 Cytek Biosciences shares in Q2 2026, an estimated $739K.
  • Cytek Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #4050 holding.
  • Ameriprise first reported a position in Cytek Biosciences in Q3 2021 and has held it in 18 quarters since.
  • Ameriprise's Cytek Biosciences position peaked at $5.16M in Q2 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.